Bristol-Myers Squibb Raises Full-Year Guidance Amid Growth Portfolio Expansion
Bristol-Myers Squibb (BMY) reported strong third-quarter 2026 results, highlighted by a 12% year-over-year revenue increase in its growth portfolio, which reached $7.7 billion. The company now boasts eight medicines that each annualize over $1 billion in sales, providing a critical buffer against upcoming patent expirations on older therapies like Eliquis. To mitigate the impact of future loss of exclusivity (LOE), management is implementing a strategic productivity initiative aimed at achieving $2 billion in cost savings. Additionally, the company's late-stage pipeline is showing momentum with four recent positive registrational studies and the accelerated FDA clearance of Symvexis for multiple myeloma. Despite an anticipated revenue step-down of $1.5 billion to $2 billion in 2027 due to European patent expirations, BMY raised its full-year adjusted EPS guidance to a range of $6.35 to $6.55, signaling confidence in its ability to balance pipeline investment with shareholder returns.

Tickers: $BMY
Topics: drug development pipeline earnings report FDA approval guidance increase revenue growth